Switzerland Cancer Pain Management Market Analysis Report [2022-30] I Insights10

Switzerland Cancer Pain Management Market Analysis

$ 3999

Switzerland's Cancer Pain Management market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The main factors driving the growth would be the aging population, advancements in pain management technology, and an increase in cancer incidence. The market is segmented by drug type and by disease. Some of the major players include Roche (CHE), Novaremed (CHE), Grunenthal Pharma, Pfizer, and Teva Pharmaceuticals.

ID: IN10CHHS002 CATEGORY: Healthcare Services GEOGRAPHY: Switzerland AUTHOR: Neha Davda

Buy Now

Switzerland Cancer Pain Management Market Executive Summary

Switzerland's Cancer Pain Management market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. In 2019, Switzerland's national healthcare spending as a share of GDP was 11.29%, amounting to $9,666.34 per person. Switzerland spent the second most on healthcare in the developed countries in 2019 behind the United States.

Cancer pain might be caused by cancer itself or by related therapies such as surgery and chemotherapy. The kind, location, and severity of pain experienced have an impact on medication choice and use. The pain caused by cancer is treated with a variety of drugs. When treating mild to moderate cancer pain, for example, it is recommended to use strong opioids rather than non-opioids such as acetaminophen and NSAIDs in cases of severe pain. Europe is a well-established player in the global market for cancer pain management, and it is also the location of some of the top pharmaceutical companies that are actively involved in the development of brand-new analgesics.

Market Dynamics

Market Growth Drivers

The Switzerland cancer pain management market is expected to be driven by factors such as the aging population, advancements in pain management technology, and an increase in cancer incidence. In Switzerland, cancer is the second most common cause of death which is rising with the rise in the aging population.

Market Restraints

Some pain relief medications come with side effects such as nausea, vertigo, urine retention, trouble sleeping, and constipation. These side effects would limit their use and have an effect on the development of the cancer pain management industry. Also, the cost of advanced pain management treatments, such as nerve blocks and implantable devices, can be high, limiting access to these treatments for some patients.

Competitive Landscape

Key Players

Roche (CHE)
Novaremed (CHE)
Grunenthal Pharma
Pfizer
Teva Pharmaceuticals

Notable Recent Deals

June 2020: Roche entered into a distribution agreement with Cipla and expand the scope of the partnership to encompass marketing and distribution of Cipla's branded cancer medications in India, including trastuzumab (Herclon), bevacizumab (Avastin), and rituximab (Ristova).

Healthcare Policies and Regulatory Landscape

Switzerland has a developed healthcare system with tight laws governing the use of drugs and medical equipment. Medical equipment and pharmaceuticals in Switzerland must be evaluated and authorized by the Swiss Agency for Therapeutic Products (Swissmedic).

Pain management is seen as a crucial aspect of cancer care, and the Swiss government supports cancer research and therapy. Before their goods may be certified for use in Switzerland, medical device makers must abide by stringent regulatory criteria to guarantee patient safety. The same is true for pharmaceutical firms, who are required to produce data from clinical trials proving the security and effectiveness of their goods.

Reimbursement Scenario

The reimbursement policy for the Swiss market for pain management aims to deliver high-quality care at a reasonable price while ensuring that patients have access to the necessary treatments. The citizens of Switzerland have access to a comprehensive healthcare system that is supported by public funds. The Swiss healthcare system typically offers reimbursement for pain management treatments; however, the specific policies and procedures may change depending on the type of treatment and the patient's unique circumstances. In general, medically required procedures are eligible for reimbursement. This covers a number of the most widely used pain management techniques, including analgesics, nerve blocks, and implanted devices.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.